MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.14
-0.78
-4.61%
After Hours: 16.14 0 0.00% 16:00 09/23 EDT
OPEN
16.96
PREV CLOSE
16.92
HIGH
16.96
LOW
16.13
VOLUME
596.29K
TURNOVER
--
52 WEEK HIGH
31.54
52 WEEK LOW
15.72
MARKET CAP
1.03B
P/E (TTM)
-3.4992
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/05 16:31
Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC
MotleyFool.com · 09/02 08:13
Theravance Biopharma to Present at Upcoming Investor Conferences
PR Newswire · 09/01 11:00
Morgan Stanley Maintains Equal-Weight on Theravance Biopharma, Lowers Price Target to $29
Morgan Stanley maintains Theravance Biopharma (NASDAQ:TBPH) with a Equal-Weight and lowers the price target from $30 to $29.
Benzinga · 08/10 13:31
Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2
Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.
Zacks · 08/07 17:27
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of -5.26% and -28.72%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/06 22:35
Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ending June 30, 2020. Revenue for the second quarter 2020 was $15.0 million. Operating loss was $72.2 million, or $55.6
PR Newswire · 08/06 20:34
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBPH. Analyze the recent business situations of Theravance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBPH stock price target is 32.00 with a high estimate of 42.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 171
Institutional Holdings: 72.04M
% Owned: 113.42%
Shares Outstanding: 63.52M
TypeInstitutionsShares
Increased
41
4.28M
New
47
1.43M
Decreased
28
4.96M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.52%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Chief Executive Officer/Director
Rick Winningham
Chief Financial Officer/Senior Vice President
Andrew Hindman
Corporate Executive
Ann Brady
Executive Vice President/General Counsel/Secretary
Bradford Shafer
Senior Vice President
Brett Haumann
Senior Vice President
.. ..
Senior Vice President
Frank Pasqualone
Senior Vice President
Kenneth Pitzer
Senior Vice President
Vijay Sabesan
Senior Vice President
Philip Worboys
Lead Director/Independent Director
William Young
Director
Robert Gunderson
Independent Director
Laurie Alsup
Independent Director
Eran Broshy
Independent Director
Burton Malkiel
Independent Director
Dean Mitchell
Independent Director
Susan Molineaux
Independent Director
Donal O'Connor
Independent Director
Deepika Pakianathan
Independent Director
George Whitesides
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.